(Q37970760)

26 August 2017

title

Crizotinib: in locally advanced or metastatic non-small cell lung cancer (English)

1 reference

26 August 2017

1 reference

1 reference

1

Monique P Curran

1 reference

26 August 2017

publication date

1 January 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

72

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

99-107

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

Targeting anaplastic lymphoma kinase in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

A mouse model for EML4-ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

The anaplastic lymphoma kinase in the pathogenesis of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207680-000000000-00000

10.2165/11207680-000000000-00000

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1007456126

0 references

1 reference